Antibody-based therapies have transformed modern medicine, offering highly specific treatments for a wide range of diseases, including cancer, autoimmune disorders, and infectious diseases. However, maximizing the therapeutic potential of antibodies often requires fine-tuning to ensure they are both highly effective and compatible with the human immune system. By increasing specificity, reducing immunogenicity, and optimizing overall performance, these antibodies can become safer and more effective treatments. Converge’s GenAI platform now opens new doors in antibody engineering, enabling precise modifications and innovations that were previously difficult to achieve.

One powerful application of Converge’s GenAI platform is the ability to modify specific parts of an existing antibody, such as in the process of antibody humanization. In humanization, researchers take an antibody from a non-human source and modify its structure to make it more compatible with the human immune system, thereby reducing the risk of an immune response. The Converge platform can predict how to optimally adjust the complementarity-determining regions (CDRs) and framework regions to maintain the antibody's binding affinity while improving its compatibility. This AI-driven approach accelerates the process, reduces trial-and-error iterations, and results in highly customized antibodies with enhanced therapeutic profiles.

In addition to modifying existing antibodies, Converge’s GenAI platform can facilitate the de novo generation of full antibodies, providing researchers with the tools to design entirely new therapeutic candidates from scratch. This capability is particularly valuable when no suitable template exists or when novel mechanisms of action are needed. The platform can simulate and design antibody structures that meet specific therapeutic goals, such as increased binding specificity or enhanced stability. Furthermore, the system also supports the design of nanobodies (VHH), which are single-domain antibodies derived from camelids that offer advantages such as smaller size and enhanced tissue penetration. This versatility enables researchers to explore a wider range of therapeutic options, from traditional antibodies to cutting-edge nanobody-based treatments, all while ensuring safety, efficacy, and patient compatibility.